BAJAJ BROKING

Notification
No new Notification messages
Anya Polytech & Fertilizers IPO is Open!
Apply for the Anya Polytech & Fertilizers IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Biocon Biologics’ YESINTEK Gets US FDA Approval for Autoimmune Diseases

Listen to our Podcast: Grow your wealth and keep it secure.

0:00 / 0:00

Synopsis:

Biocon Biologics’ YESINTEK, a monoclonal antibody for autoimmune diseases, secures US FDA approval. Collaboration with Janssen targets commercialisation by February 2025.

Biocon Biologics has announced the US Food and Drug Administration (FDA) approval of YESINTEK, a monoclonal antibody developed to treat chronic autoimmune diseases. The drug addresses conditions like Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. By targeting proteins responsible for inflammation, YESINTEK offers a novel treatment option, advancing care for patients managing these lifelong conditions. The approval reinforces Biocon Biologics’ strategic focus on the US market, potentially influencing the Biocon Biologics share price positively.

Also read: Jet Fuel ATF Prices Surge 1.45% in Delhi, LPG Rates Also Hiked

BIOCON LIMITED.

Trade

346.451.95 (0.56 %)

Updated - 26 December 2024
347.90day high
DAY HIGH
339.90day low
DAY LOW
3134559
VOLUME (BSE)

Key Takeaways

  • FDA Approval Date: Announced in 2024.

  • Target Diseases: Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.

  • Collaboration: Partnership with Janssen Biotech, Janssen Sciences Ireland, and Johnson & Johnson.

  • Market Launch: Targeted by February 22, 2025.

Also read: Hero Future Energies to Invest ₹11,000 Crore in Karnataka’s Green Energy

YESINTEK FDA Approval: Timeline and Collaboration

Aspect

Details

Approval Date

2024

Commercialisation Target

No later than February 22, 2025

Key Collaborators

Janssen Biotech, Johnson & Johnson

Focus Market

United States

The licensing agreement with Janssen Biotech, announced earlier this year, paves the way for commercialisation of YESINTEK in the U.S. The collaboration aims to accelerate the drug’s availability, leveraging Janssen’s healthcare expertise.

Expanding Biocon Biologics’ Global Presence

This approval is a significant milestone for Biocon Biologics, marking its growing footprint in the U.S. healthcare market. The company’s focus on developing and commercialising advanced therapies aligns with its broader objectives of addressing unmet medical needs. The milestone could bolster the Biocon Biologics share price, reflecting investor confidence in the company’s expanding product portfolio.

Enhancing Treatment Options for Autoimmune Diseases

YESINTEK’s approval brings a promising solution for millions affected by autoimmune disorders. By targeting inflammation-causing proteins, the drug aims to reduce disease symptoms and improve patient outcomes. This achievement underscores Biocon Biologics’ commitment to pioneering solutions in biotechnology.

The US FDA approval of YESINTEK is a pivotal moment for Biocon Biologics, setting the stage for its strengthened presence in the U.S. pharmaceutical market. With strategic partnerships and innovative therapies, the company continues to make strides in addressing critical healthcare challenges.

Also read: Greaves Cotton Approves IPO for Electric Mobility Arm GEML

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://bit.ly/3Tcsfuc

Share this article: 

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs+ Users

icon-with-text

4.4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4700+ Cr MTF Book

icon-with-text